Related references
Note: Only part of the references are listed.Methionine enkephalin (MENK) suppresses lung cancer by regulating the Bcl-2/Bax/caspase-3 signaling pathway and enhancing natural killer cell-driven tumor immunity
Shuling Zhang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
Cytotoxic Effect of Cord Blood Derived Natural Killer Cells on Breast Cancer Cells
Ayfer Karlitepe et al.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY (2021)
Killer Immunoglobulin-Like Receptor 2DL4 (CD158d) Regulates Human Mast Cells both Positively and Negatively: Possible Roles in Pregnancy and Cancer Metastasis
Tatsuki R. Kataoka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Exploiting antibody biology for the treatment of cancer
Vidhi Khanna et al.
IMMUNOTHERAPY (2020)
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking
Anna H. Turaj et al.
SCIENTIFIC REPORTS (2018)
MicroRNA 603 acts as a tumor suppressor and inhibits triplenegative breast cancer tumorigenesis by targeting elongation factor 2 kinase
Recep Bayraktar et al.
ONCOTARGET (2017)
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation
Alexander M. Lesokhin et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
Isabelle Le Mercier et al.
FRONTIERS IN IMMUNOLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Bo Yuan Huang et al.
PLOS ONE (2015)
A personalized view on cancer immunotherapy
Laura Wayteck et al.
CANCER LETTERS (2014)
Infusions of Allogeneic Natural Killer Cells as Cancer Therapy
Wing Leung
CLINICAL CANCER RESEARCH (2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin et al.
LANCET ONCOLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells
Ignacio Melero et al.
CLINICAL CANCER RESEARCH (2013)
Treatment of patients with advanced cancer with the natural killer cell line NK-92
Torsten Tonn et al.
CYTOTHERAPY (2013)
被撤回的出版物: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Natural killer cells and hepatitis C: action and reaction
Kuldeep Cheent et al.
GUT (2011)
Activating and inhibitory receptors of natural killer cells
Hollie J. Pegram et al.
IMMUNOLOGY AND CELL BIOLOGY (2011)
Natural killer cell-based immunotherapy in cancer: current insights and future prospects
T. Sutlu et al.
JOURNAL OF INTERNAL MEDICINE (2009)
The genotype of the NK cell receptor, KIR2DL4, influences INFγ secretion by decidual natural killer cells
J. P. Goodridge et al.
MOLECULAR HUMAN REPRODUCTION (2009)
Up on the tightrope: natural killer cell activation and inhibition
Lewis L. Lanier
NATURE IMMUNOLOGY (2008)
Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host
Cunren Liu et al.
BLOOD (2007)
NK cell regulation of T cell-mediated responses
A Zingoni et al.
MOLECULAR IMMUNOLOGY (2005)
Cutting edge:: induction of IFN-γ production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells
S Rajagopalan et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
